Citrobacter Freundii is a bacterium that belongs to the
Citrobacter species and the Enterobacteriaceae family. It is a
rod-shaped, aerobic, gram-negative bacterium that is about one to five
micrometers in length. Most of the C-Freundii bacteria have flagella
around them that they use for movement. However, a few types are
non-motile.
C-Freundii can be responsible for a wide number of opportunistic infections in patients in a hospital or clinic. The term 'opportunistic infection' is used for infections that cannot happen in normal healthy individuals, but only in people with low immunity, like patients who are undergoing sickness. In other words, C-Freundii would need specific opportunities to infect people and they cannot infect anyone who is healthy.
People who have infections induced by the bacteria would often respond to C-Freundii treatment consisting of antibiotic drugs. Some of the drugs used for C-Freundii treatment include antibiotics like Amikacin, Amikin, Avelox, Cefepime, Cefotetan, Ceftazidime, Ceftin, Ceftriaxone, Cefuroxime, Chibroxin, Cipro, Ciprofloxacin, Doribax, Doripenem, Ertapenem, Fortaz, Fosfomycin, Furadantin, Kanamycin, Levaquin, Levofloxacin, Macrobid, Macrodantin, Maxipime, Monurol, Moxifloxacin, Nitrofurantoin, Norfloxacin, Norfloxacin Ophthalmic, Noroxin, Ofloxacin, Piperacillin, Proquin XR, Rocephin, and Tazicef.
While this bacteria causes nosocomial infections in patients, it is very useful for the environment. The bacteria inhabit soil, water and sewage and they play a crucial role in reducing nitrate to nitrite which is a very important step in the nitrogen cycle. Considering that the atmosphere of the earth consists of 85% nitrogen, the important role of this microbe can be really appreciated.
The genome of the microbe is being sequenced in order to find effective C-Freundii treatment options for patients. The positive role of the bacteria in recycling nitrogen in the atmosphere is another reason for studying the bacteria in detail.
Neonatal meningitis is the only fatal disease that is directly caused by C-Freundii, with death rates in patients ranging from 25% to 50%. Therefore, the study of C-Freundii treatment becomes all the more relevant and important. It was reported recently that C-Freundii shows resistance to broad-spectrum antibiotics like piperacillintazobactam, vancomycin, piperacillin and cephalosporins. Ceftriaxone is another drug for which C-Freundii has developed resistance due to over-prescription of broad-spectrum antibiotics. In patients with peripheral vascular disease, cerebrovascular disease, AIDS and others with significant comorbidities, the ceftriaxone-resistant C-Freundii have been more or less isolated.
Since C-freundii is mostly responsible for nosocomial infections, physicians are advised to exercise caution against new strains that could develop resistance to C-Freundii treatment.
C-Freundii can be responsible for a wide number of opportunistic infections in patients in a hospital or clinic. The term 'opportunistic infection' is used for infections that cannot happen in normal healthy individuals, but only in people with low immunity, like patients who are undergoing sickness. In other words, C-Freundii would need specific opportunities to infect people and they cannot infect anyone who is healthy.
People who have infections induced by the bacteria would often respond to C-Freundii treatment consisting of antibiotic drugs. Some of the drugs used for C-Freundii treatment include antibiotics like Amikacin, Amikin, Avelox, Cefepime, Cefotetan, Ceftazidime, Ceftin, Ceftriaxone, Cefuroxime, Chibroxin, Cipro, Ciprofloxacin, Doribax, Doripenem, Ertapenem, Fortaz, Fosfomycin, Furadantin, Kanamycin, Levaquin, Levofloxacin, Macrobid, Macrodantin, Maxipime, Monurol, Moxifloxacin, Nitrofurantoin, Norfloxacin, Norfloxacin Ophthalmic, Noroxin, Ofloxacin, Piperacillin, Proquin XR, Rocephin, and Tazicef.
While this bacteria causes nosocomial infections in patients, it is very useful for the environment. The bacteria inhabit soil, water and sewage and they play a crucial role in reducing nitrate to nitrite which is a very important step in the nitrogen cycle. Considering that the atmosphere of the earth consists of 85% nitrogen, the important role of this microbe can be really appreciated.
The genome of the microbe is being sequenced in order to find effective C-Freundii treatment options for patients. The positive role of the bacteria in recycling nitrogen in the atmosphere is another reason for studying the bacteria in detail.
Neonatal meningitis is the only fatal disease that is directly caused by C-Freundii, with death rates in patients ranging from 25% to 50%. Therefore, the study of C-Freundii treatment becomes all the more relevant and important. It was reported recently that C-Freundii shows resistance to broad-spectrum antibiotics like piperacillintazobactam, vancomycin, piperacillin and cephalosporins. Ceftriaxone is another drug for which C-Freundii has developed resistance due to over-prescription of broad-spectrum antibiotics. In patients with peripheral vascular disease, cerebrovascular disease, AIDS and others with significant comorbidities, the ceftriaxone-resistant C-Freundii have been more or less isolated.
Since C-freundii is mostly responsible for nosocomial infections, physicians are advised to exercise caution against new strains that could develop resistance to C-Freundii treatment.
0 comments:
Post a Comment